Scholarlink

<p>Advances in cancer therapeutics have significantly improved patient survival; however, cardiotoxic effects—including arrhythmias—have emerged as a growing clinical concern. This expert opinion, developed by the Working Groups on Cardio-Oncology and Electrophysiology of the Hellenic Cardiological Society, aims to raise awareness of the increasing burden of arrhythmias in cancer patients and survivors. This document explores the multifactorial etiology of arrhythmias in this population, including patient-related factors, the direct effects of malignancy, and the arrhythmogenic potential of therapies such as classical chemotherapy, targeted agents, immunotherapy, hormonal treatments, and radiotherapy. Additionally, the often-overlooked contributors—such as autonomic dysfunction and drug–drug interactions— are discussed and emphasis is put on specific diagnostic and management challenges. It provides practical insights into the spectrum of arrhythmias and conduction disorders, including atrial fibrillation, QTc prolongation, and sudden cardiac death, while underscoring the importance of comprehensive cardiologic assessment throughout the cancer care continuum.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the hellenic cardiac society

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Kalliopi Keramida,
  • Ourania Kariki,
  • Eleni Angelopoulou,
  • Ioannis Kalafatis,
  • Christos Lafaras,
  • Konstantinos P. Letsas,
  • Helena Michalopoulou,
  • Athanasios Saplaouras,
  • Konstantinos Tampakis,
  • Dorothea Tsekoura,
  • George Andrikopoulos

摘要

Advances in cancer therapeutics have significantly improved patient survival; however, cardiotoxic effects—including arrhythmias—have emerged as a growing clinical concern. This expert opinion, developed by the Working Groups on Cardio-Oncology and Electrophysiology of the Hellenic Cardiological Society, aims to raise awareness of the increasing burden of arrhythmias in cancer patients and survivors. This document explores the multifactorial etiology of arrhythmias in this population, including patient-related factors, the direct effects of malignancy, and the arrhythmogenic potential of therapies such as classical chemotherapy, targeted agents, immunotherapy, hormonal treatments, and radiotherapy. Additionally, the often-overlooked contributors—such as autonomic dysfunction and drug–drug interactions— are discussed and emphasis is put on specific diagnostic and management challenges. It provides practical insights into the spectrum of arrhythmias and conduction disorders, including atrial fibrillation, QTc prolongation, and sudden cardiac death, while underscoring the importance of comprehensive cardiologic assessment throughout the cancer care continuum.